Factors affecting adherence to medications in people with attention-deficit/hyperactivity disorder (ADHD) are not well understood in the context of their influence on the different phases of adherence, that is, initiation, implementation, and discontinuation. This review aimed to identify the factors affecting the three phases of medication adherence in people with ADHD.
Methods:
Six electronic databases, including Medline, PubMed, IPA, CINAHL, Embase, and PsycINFO, were systematically searched from inception through October 2018 with the limitations of English language and human studies. The search strategy was based on three concepts (adherence, ADHD, and factors) and their relevant terminologies.
Results:
Considerable variability was observed with regards to the criteria used to define adherence in identified studies (n = 48). Most studies focused on the implementation phase of adherence (n = 27), while only a handful focused on the initiation (n = 6) and discontinuation (n = 5) phase of adherence. The remaining studies (n = 10) examined multiple phases of adherence. Conflicting information received about medication, medication frequency, and fears of medication's effect on growth were the unique factors impacting initiation, implementation, and discontinuation, respectively. Moreover, factors within each phase of adherence also differed with different populations such as parents, children, adolescents, and adults. Fear of addiction, medication effectiveness, psychiatric comorbidity, and medication side effects were the most common factors identified in all three phases of adherence.
Conclusions:
This review found some unique factors in each phase of adherence while some overlap was also noted. Future interventions to improve adherence should be phase- and group specific rather than consider adherence as a single variable.
Get full access to this article
View all access options for this article.
References
1.
AdlerLD, NierenbergAA: Review of medication adherence in children and adults with ADHD. Postgrad Med, 122:184–191, 2010.
2.
AhmedR, AslaniP.What is patient adherence? A terminology overview. Int J Clin Pharm, 36:4–7, 2014.
3.
AhmedR, AslaniP: Attention-deficit/hyperactivity disorder: An update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res, 13:791–815, 2013.
4.
AhmedR, AslaniP: Impact of gender on adherence to therapy. J Malta Coll Pharm Prac, 20:21–23, 2014.
5.
AhmedR, BorstJ, WeiYC, AslaniP: Parents' perspectives about factors influencing adherence to pharmacotherapy for ADHD. J Atten Disord, 21:91–99, 2017.
6.
AntonyA: Study of factors influencing treatment adherence in childhood attention deficit hyperactivity disorder in a tertiary healthcare facility. Indian J Psychol Med, 38:20–24, 2016.
7.
AtzoriP, UsalaT, CarucciS, DanjouF, Zuddas: Predictive factors for persistent use and compliance of immediate-release methylphenidate: A 36-month naturalistic study. J Child Adolesc Psychopharmacol, 19:673–681, 2009.
8.
AyazM, AyazAB, SoyluN, YükselS: Medication persistence in Turkish children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 24:442–447, 2014.
9.
BahmanyarS, SundströmA, KaijserM, von KnorringA-L, KielerH: Pharmacological treatment and demographic characteristics of pediatric patients with attention deficit hyperactivity disorder, Sweden. Eur Neuropsychopharmacol, 23:1732–1738, 2013.
10.
BaliV, KamblePS, AparasuRR: Cardiovascular safety of concomitant use of atypical antipsychotics and long-acting stimulants in children and adolescents with ADHD. J Atten Disord, 23:163–172, 2015.
11.
BanekK, LalaniM, StaedkeSG, ChandramohanD: Adherence to artemisinin-based combination therapy for the treatment of malaria: A systematic review of the evidence. Malar J, 13:7, 2014.
12.
BarnerJC, KhozaS, OladapoA: ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin, 27:13–22, 2011.
13.
BejerotS, RydénEM, ArlindeCM: Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: A prospective study. J Clin Psychiatry, 71:1590–1597, 2010.
14.
BhangSY, KwackYS, JoungYS, LeeSI, KimB, SohnSH, ChungUS, YangJ, HongM, BahnGH, ChoiHY: Factors that affect the adherence to ADHD medications during a treatment continuation period in children and adolescents: A nationwide retrospective cohort study using korean health insurance data from 2007 to 2011. Psychiatry Invest, 14:158–165, 2017.
15.
BijlengaD, KulcuS, van GellecumT, EryigitZ, KooijJS: Persistence and adherence to psychostimulants, and psychological well-being up to 3 years after specialized treatment of adult attention-deficit/hyperactivity disorder: A naturalistic follow-up study. J Clin Psychopharmacol, 37:689–696, 2017.
16.
BondDJ, HadjipavlouG, LamRW, McIntyreRS, BeaulieuS, SchafferA, WeissM: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry, 24:23–37, 2012.
17.
BrettJ, KarangesEA, DanielsB, BuckleyNA, SchneiderC, NassirA, ZoegaH, McLachlanAJ, PearsonSA: Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry, 51:990–999, 2017.
18.
BrinkmanWB, ShermanSN, ZmitrovichAR, VisscherMO, CrosbyLE, PhelanKJ, DonovanEF: In their own words: Adolescent views on ADHD and their evolving role managing medication. Acad Pediatr, 12:53–61, 2012.
19.
BrownMT, BussellJK: Medication adherence: WHO cares?. Mayo Clin Proc, 4: 304–314, 2011.
20.
BrunnerR, Dunbar-JacobJ, LeBoffMS, GranekI, BowenD, SnetselaarLG, ShumakerSA, OckeneJ, RosalM, Wactawski-WendeJ, CauleyJ: Predictors of adherence in the women's health initiative calcium and vitamin D trial. Behav Med, 34:145–155, 2009.
21.
BuchananAL, MontepiedraG, SiroisPA, KammererB, GarviePA, StormDS, NicholsSL: Barriers to medication adherence in HIV-infected children and youth based on self-and caregiver report. Pediatrics, 129:e1244–e1251, 2012.
22.
CaisleyH, MüllerU: Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review. Eur Psychiatry, 27:343–349, 2012.
23.
Centre for Reviews and Dissemination: Systematic reviews: CRD's guidance for undertaking reviews in health care [Internet]. Available at: www.york.acuk/inst/crd/index_guidance.htm. Accessed 19th January, 2010.
24.
CharachA, GajariaA: Improving psychostimulant adherence in children with ADHD. Expert Rev Neurother, 8:1563–1571, 2008.
25.
CharachA, SkybaA, CookL, AntleBJ: Using stimulant medication for children with ADHD: What do parents say?. A brief report. J Can Acad Child Adolesc Psychiatry, 15:75, 2006.
26.
ChenCY, GerhardT, WintersteinAG: Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 19:187–195, 2009.
27.
ChenCY, YehHH, ChenKH, ChangIS, WuECH, LinKM: Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 21:265–273, 2011.
28.
ChienIC, LinCH, ChouYJ, ChouP: Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996–2005: A national population-based study. Soc Psychiatry Psychiatr Epidemiol, 47:1885–1890, 2012.
29.
ChildressAC, SalleeFR: Attention-deficit/hyperactivity disorder with inadequate response to stimulants: Approaches to management. CNS Drugs, 28:121–129, 2014
30.
CokerTR, ElliottMN, Toomey SL SchwebelDC, CuccaroP, Tortolero EmeryS, DaviesSL, VisserSN, SchusterMA: Racial and ethnic disparities in ADHD diagnosis and treatment. Pediatric, 138:e20160407, 2016.
31.
ColettiDJ, PappadopulosE, KatsiotasNJ, BerestA, JensenPS, KafantarisV: Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 22:226–237, 2012.
32.
CormierE: How parents make decisions to use medication to treat their child's ADHD: A grounded theory study. J Am Psychiatr Nurses Assoc, 18:345–356, 2012.
33.
CramerJA, RoyA, BurrellA, FairchildCJ, FuldeoreMJ, OllendorfDA, WongPK: Medication compliance and persistence: Terminology and definitions. Value Health, 11:44–47, 2008.
34.
CuffeSP, VisserSN, HolbrookJR, DanielsonML, GerykLL, WolraichML, McKeownRE: ADHD and psychiatric comorbidity: Functional outcomes in a school-based sample of children. J Attention, Disorders:1087054715613437, 2015.
35.
DarredeauC, BarrettSP, JardinB, PihlRO: Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol, 22:529–536, 2007.
36.
de GraafR, KesslerRC, FayyadJ, ten HaveM, AlonsoJ, AngermeyerM, BorgesG, DemyttenaereK, GasquetI, de GirolamoG: The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: Results from the WHO World Mental Health Survey Initiative. Occup Environ Med, 65:835–842, 2008.
37.
Dixon-WoodsM, AgarwalS, JonesD, YoungB, SuttonA: Synthesising qualitative and quantitative evidence: A review of possible methods. J Health Serv Res Policy, 10:45–53, 2005.
38.
DopheideJ: The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care, 15:S141–S150, 2009.
39.
DosreisS, MyersMA: Parental attitudes and involvement in psychopharmacological treatment for ADHD: A conceptual model. Int Rev Psychiatry, 20:135–141, 2008.
40.
EmilssonM, GustafssonPA, ÖhnströmG, MarteinsdottirI: Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry, 26:559–571, 2017.
41.
FaraoneSV, BiedermanJ, ZimmermanB: An analysis of patient adherence to treatment during a 1-year, open-label study of OROS® methylphenidate in children with ADHD. J Atten Disord, 11:157–166, 2007.
42.
FerrinM, TaylorE: Child and caregiver issues in the treatment of attention deficit–hyperactivity disorder: Education, adherence and treatment choice. Future Neurol, 6:399–413, 2011.
FiksAG, MayneS, LocalioAR, AlessandriniEA, GuevaraJP: Shared decision-making and health care expenditures among children with special health care needs. Pediatrics, 129:99–107, 2012.
45.
FrankE, OzonC, NairV, OtheeK: Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: A review and analysis. J Clin Psychiatry, 76:e1459–e1468, 2015.
46.
GajriaK, LuM, SikiricaV: Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder–a systematic literature review. Neuropsychiatr Dis Treat, 10:1543–1569, 2014.
47.
GarbeE, MikolajczykRT, Banaschewski T PetermannU, PetermannF, KrautAA, LangnerI: Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: Results from a large population-based cohort study. J Child Adolesc Psychopharmacol, 22:452–458, 2012.
48.
GauS, ChenSJ, ChouWJ, ChengH, TangCS, ChangHL, TzangRF, WuYY, HuangYF, ChouMC: National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry, 69:131–140, 2008.
49.
GauSS, ShenHY, ChouMC, TangCS, ChiuYN, GauCS: Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol, 16:286–297, 2006.
50.
GebbiaV, BellaviaG, FerraùF, ValerioMR: Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf, 11:S49–S59, 2012.
51.
GhanizadehA: Educating and counseling of parents of children with attention-deficit hyperactivity disorder. Patient Educ Couns, 68:23–28, 2007.
52.
GillespieD, FarewellD, Brookes-HowellL, ButlerCC, CoenenS, FrancisNA, LittleP, StuartB, VerheijT, HoodK: Determinants of initiation, implementation, and discontinuation of amoxicillin by adults with acute cough in primary care. Patient Pref Adherence, 11:561, 2017.
53.
GraetzBW, SawyerMG, HazellPL, ArneyF, BaghurstP: Validity of DSM-IV ADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry, 40:1410–1417, 2001.
54.
GreydanusDE, KaplanG: Strategies to improve medication adherence in youths: Approaches during the active to maintenance transition. Psychiatr Times, 29:14–14, 2012.
55.
HaynesRB.Determinants of Compliance: The Disease and the Mechanics of Treatment. Baltimore: MD, Johns Hopkins University Press, 1979
56.
HearnshawH, LindenmeyerA: What do we mean by adherence to treatment and advice for living with diabetes?. A review of the literature on definitions and measurements. Diabet Med, 23:720–728, 2006.
57.
HebertJ, PolotskaiaA, JooberR, GrizenkoN: Adherence to psychostimulant medication in children with attention-deficit/hyperactivity disorder: The role of attitudes. J Can Acad Child Adolesc Psychiatry, 22:317, 2013.
58.
HodgkinsP, SasanéR, ChristensenL, HarleyC, LiuF: Treatment outcomes with methylphenidate formulations among patients with ADHD: Retrospective claims analysis of a managed care population. Curr Med Res Opin, 27:53–62, 2011.
59.
HongJ, NovickD, TreuerT, MontgomeryW, HaynesVS, WuS, HaroJM: Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia. Patient Preference Adherence, 7:987, 2013.
60.
HongM, KimB, HwangJ-W, BhangS-Y, ChoiHY, OhI-H, LeeYJ, BahnGH: Naturalistic pharmacotherapy compliance among pediatric patients with attention deficit/hyperactivity disorder: A study based on three-year nationwide data. J Korean Med Sci, 31:611–616, 2016.
61.
HongM, LeeWH, MoonDS, LeeSM, ChungU-S, BahnGH: A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 24:341–346, 2014.
62.
JensenML, JørgensenME, HansenEH, AagaardL, CarstensenB. Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation. PLoS One, 12:e0179546, 2017.
63.
JensenPS: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 56:1073–1086, 1999.
64.
JimmyB, JoseJ: Patient medication adherence: Measures in daily practice. Oman Med J, 26:155, 2011.
65.
KavS, JohnsonJ, RittenbergC, Fernadez-OrtegaP, SuominenT, OlsenPR, PatirakiE, PorockD, DahlerA, ToliusieneJ: Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: An international survey. Support Care Cancer, 16:1075–1083, 2008.
66.
KooijJS, RöslerM, PhilipsenA, WächterS, DejonckheereJ, van der KolkA, van AgthovenM, SchäubleB: Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: Results from a randomized, placebo-controlled trial. BMC Psychiatry, 13:36, 2013.
67.
LakhanpaulM, BirdD, ManikamL, CulleyL, PerkinsG, HudsonN, WilsonJ, JohnsonM: A systematic review of explanatory factors of barriers and facilitators to improving asthma management in South Asian children. BMC Public Health, 14:403, 2014.
68.
LiY, LiuW, ZhuY, LiuX, WintersteinAG. Determinants of Pharmacological Treatment Initiation and Persistence in Publicly Insured Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol, 37:546–554, 2017.
69.
ManteuffelM, WilliamsS, ChenW, VerbruggeRR, PittmanDG, SteinkellnerA: Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health, 23:112–119, 2014.
70.
McQuaidEL, KopelSJ, KleinRB, FritzGK: Medication adherence in pediatric asthma: Reasoning, responsibility, and behavior. J Pediatr Psychol, 28:323–333, 2003.
71.
MillerAR, LalondeCE, McGrailKM: Children's persistence with methylphenidate therapy: A population-based study. Can J Psychiatry, 49:761–768, 2004.
72.
MoherD, LiberatiA, TetzlaffJ, AltmanDG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med, 151:264–269, 2009.
73.
MonastraVJ: Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: A neuro-educational approach. Int J Psychophysiol, 58:71–80, 2005.
74.
MontejanoL, SasanéR, HodgkinsP, RussoL, HuseD: Adult ADHD: Prevalence of diagnosis in a US population with employer health insurance. Curr Med Res Opin, 27:5–11, 2011.
75.
MurrayDW, ArnoldLE, SwansonJ, WellsK, BurnsK, JensenP, HechtmanL, PaykinaN, LegatoL, StraussT: A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep, 10:424–431, 2008.
76.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management. Available at: www.nice.org.uk/guidance/cg72/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-975625063621. Last updated 2018. Accessed 30 October, 2018.
77.
NauDP, AikensJE, PacholskiAM: Effects of gender and depression on oral medication adherence in persons with type 2 diabetes mellitus. Gend Med, 4:205–213, 2007.
78.
O'CallaghanP: Adherence to stimulants in adult ADHD. Atten Defic Hyperact Disord, 6:111–120, 2014.
79.
OsterbergL, BlaschkeT: Adherence to medication. N Engl J Med, 353:487–497, 2005.
80.
PalliSR, KamblePS, ChenH, AparasuRR: Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 22:139–148, 2012.
81.
PittmanDG, ChenW, BowlinSJ, FoodyJM: Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol, 107:1662–1666, 2011.
82.
PolanczykG, De LimaMS, HortaBL, BiedermanJ, RohdeLA: The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry, 164:942–948, 2007.
83.
PolanczykGV, WillcuttEG, SalumGA, KielingC, RohdeLA: ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. Int J Epidemiol, 43:434–442, 2014.
84.
PopayJ, RobertsH, SowdenA, PetticrewM, AraiL, RodgersM, BrittenN, RoenK, DuffyS: Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. A Product from the ESRC Methods Programme. Version 1:b92. Swindon, United Kingdom, Economic and Social Research Council, 2006.
85.
RamanSR, ManKK, BahmanyarS, BerardA, BilderS, BoukhrisT, BushnellG, CrystalS, FuruK, KaoYangYH, Karlstad Ø: Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. Lancet Psychiatry, 5:824–835, 2018.
86.
RamanSR, MarshallSW, GaynesBN, HaynesK, NaftelAJ, StürmerT: An observational study of pharmacological treatment in primary care of children with ADHD in the United Kingdom. Psychiatr Serv, 66:617–624, 2015.
87.
RieppiR, GreenhillLL, FordRE, ChuangS, WuM, DaviesM, AbikoffHB, ArnoldLE, ConnersCK, ElliottGR: Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry, 41:269–277, 2002.
88.
RucklidgeJJ: Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin, 33:357–373, 2010.
89.
SafrenSA, DuranP, YovelI, PerlmanCA, SprichS: Medication adherence in psychopharmacologically treated adults with ADHD. J Atten Disord, 10:257–260, 2007.
90.
SayalK, PrasadV, DaleyD, FordT, CoghillD: ADHD in children and young people: Prevalence, care pathways, and service provision. Lancet Psychiatry, 5:175–186, 2018.
91.
SchaeferMR, RawlinsonAR, WagonerST, ShapiroSK, KavookjianJ, GrayWN: Adherence to attention-deficit/hyperactivity disorder medication during the transition to college. J Adolesc Health, 60:706–713, 2017.
92.
SchommerM: Effects of beliefs about the nature of knowledge on comprehension. J Educ Psychol, 82:498, 1990.
93.
SemerciB, TaskıranS, TufanE, ŞanliI: Factors predicting treatment adherence in patients with adult attention-deficit/hyperactivity disorder: A preliminary study. Atten Defic Hyperact Disord, 8:139–147, 2016.
94.
SitholeyP, AgarwalV, ChamoliS: A preliminary study of factors affecting adherence to medication in clinic children with attention-deficit/hyperactivity disorder. Indian J Psychiatry, 53:41, 2011.
95.
SkoglundC, BrandtL, Almqvist C D'OnofrioBM, KonsteniusM, FranckJ, LarssonH: Factors associated with adherence to methylphenidate treatment in adult patients with attention-deficit/hyperactivity disorder and substance use disorders. J Clin Psychopharmacol, 36:222–228, 2016.
96.
SleathB, CarpenterDM, SaynerR, ThomasK, MannL, SageA, SulzerSH, SandlerAD. Youth views on communication about ADHD and medication adherence. Community Ment Health J, 53:438–444, 2017.
97.
SobanskiE, RetzW, FischerR, OseC, AlmB, HennigO, RöslerM: Treatment adherence and persistence in adult ADHD: Results from a twenty-four week controlled clinical trial with extended release methylphenidate. Eur Psychiatry, 29:324–330, 2014.
98.
SpencerTJ, FaraoneSV, MichelsonD, AdlerLA, ReimherrFW, GlattSJ, BiedermanJ: Atomoxetine and adult attention-deficit/hyperactivity disorder: The effects of comorbidity. J Clin Psychiatry, 67:415–420, 2006.
99.
SrimongkonP, AslaniP, ChenTF: Consumer-related factors influencing antidepressant adherence in unipolar depression: A qualitative study. Patient Pref Adherence, 12:1863, 2018.
100.
SwansonJ: Compliance with stimulants for attention-deficit/hyperactivity disorder. CNS Drugs, 17:117–131, 2003.
101.
ThiruchelvamD, CharachA, SchacharRJ: Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry, 40:922–928, 2001.
102.
ThorellLB, DahlströmK: Children's self-reports on perceived effects on taking stimulant medication for ADHD. J Atten Disord, 12:460–468, 2009.
103.
ToomeySL, SoxCM, RusinakD, FinkelsteinJA: Why do children with ADHD discontinue their medication?. Clin Pediatr (Phila), 51:763–769, 2012.
104.
TorgersenT, GjervanB, NordahlHM, RasmussenK: Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: A retrospective, naturalistic study. J Clin Psychopharmacol, 32:645–652, 2012.
105.
TreuerT, FengQ, DesaiahD, AltinM, WuS, El-ShafeiA, SerebryakovaE, GadoM, FariesD: Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates. Int J Clin Pract, 68:1152–1160, 2014.
106.
TreuerT, MéndezL, MontgomeryW, WuS: Factors affecting treatment adherence to atomoxetine in ADHD: A systematic review. Neuropsychiatr Dis Treat, 12:1061, 2016.
107.
van den BanE, SouvereinPC, SwaabH, van EngelandH, EgbertsTC, HeerdinkER: Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. J Atten Disord, 2:213–220, 2010.
108.
VerbruggheM, VerhaegheS, LauwaertK, BeeckmanD, Van HeckeA: Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treat Rev, 39:610–621, 2013.
109.
VermeireE, HearnshawH, Van RoyenP, DenekensJ: Patient adherence to treatment: Three decades of research. A comprehensive review. J Clin Pharm Ther, 26:331–342, 2001.
110.
VrijensB, De GeestS, HughesDA, PrzemyslawK, DemonceauJ, RupparT, DobbelsF, FargherE, MorrisonV, LewekP: A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol, 73:691–705, 2012.
111.
WangLJ, YangKC, LeeSY, YangCJ, HuangTS, LeeTL, YuanSS, ShyuYC: Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan. PLoS One, 11:e0161061, 2016.
112.
WehmeierPM, DittmannRW, BanaschewskiT: Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: Results from the COMPLY observational study. Atten Defic Hyperact Disord, 7:165–174, 2015.
113.
WilensTE, AdamsonJ, Monuteaux MC FaraoneSV, SchillingerM, WesterbergD, BiedermanJ: Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med, 162:916–921, 2008.
114.
WillcuttEG: The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics, 9:490–499, 2012.
115.
WintersteinAG, GerhardT, Shuster J ZitoJ, JohnsonM, LiuH, SaidiA: Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother, 42:24–31, 2008.
116.
WongI, AshersonP, BilbowA, CliffordS, CoghillD, DeSoysaR, HollisC, McCarthyS, MurrayM, PlannerC: Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)–a pharmacoepidemiological and qualitative study. Health Technol Assess, 13:1–120, 2009.
117.
World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization; 2003. https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1 Accessed 10 January, 2019.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
